Plasma uric acid is related to large arterial stiffness but not to other hemodynamic variables: a study in 606 normotensive and never-medicated hypertensive subjects

Humam Hamid1†, Venla Kurra1†, Manoj Kumar Choudhary1, Heidi Bouquin1, Onni Niemelä1,2, Mika A. P. Kähönen1,3, Jukka T. Mustonen1,4, Ilkka H. Pörsti1,4* and Jenni K. Koskela1,4

Abstract
Background: Elevated level of plasma uric acid (PUA) has been associated with cardiovascular disease, but whether uric acid is an independent risk factor or merely a marker remains controversial.

Methods: We investigated in a cross-sectional setting the association of PUA with hemodynamics in 606 normotensive and never-medicated hypertensive subjects (295 men, 311 women, age range 19–73 years) without cardiovascular disease or gout. In all except 15 individuals, PUA was within the normal range. Supine hemodynamics were recorded using whole-body impedance cardiography and radial tonometric pulse wave analysis.

Results: The mean concentrations of PUA in age, sex and body mass index adjusted quartiles were 234, 278, 314, and 373 µmol/l, respectively. The highest PUA quartile presented with higher aortic to popliteal pulse wave velocity (PWV) than the lowest quartile (8.7 vs. 8.2 m/s, \( p = 0.026 \)) in analyses additionally adjusted for plasma concentrations of C-reactive protein, low density lipoprotein cholesterol, triglycerides, and mean aortic blood pressure. No differences in radial and aortic blood pressure, wave reflections, heart rate, cardiac output, and systemic vascular resistance were observed between the quartiles. In linear regression analysis, PUA was an independent explanatory factor for PWV (\( \beta = 0.168, p < 0.001, R^2 \) of the model 0.591), but not for systolic or diastolic blood pressure. When the regression analysis was performed separately for men and women, PUA was an independent predictor of PWV in both sexes.

Conclusions: PUA concentration was independently and directly associated with large arterial stiffness in individuals without cardiovascular disease and PUA levels predominantly within the normal range. Trial registration ClinicalTrials.gov NCT01742702.

Keywords: Arterial stiffness, Hemodynamics, Impedance cardiography, Pulse wave analysis, Uric acid

Background
Cardiovascular disease (CVD) is the leading cause of death worldwide [1]. The World Health Organization estimates that 17.9 million people died from CVDs in 2016, which represents 31% of all global deaths [1]. The role of uric acid, the final product of purine degradation [2], in the development and progression of CVDs has been a subject for an ongoing debate [3, 4].
An umbrella review analyzing systematic reviews, meta-analyses, and Mendelian randomization studies was recently conducted to investigate uric acid’s role in various health outcomes [3]. The outcome was that convincing evidence of a clear role for uric acid existed only regarding nephrolithiasis and gout, whilst suggestive evidence was observed with heart failure, hypertension, impaired fasting glucose or diabetes, chronic kidney disease, and coronary heart disease [3].

One possible link between uric acid and CVD is through arterial stiffness. Decreased large arterial compliance is an acknowledged prognostic marker for CVDs [5, 6]. The recording of pulse wave velocity (PWV) is regarded as the gold standard in the evaluation of large arterial stiffness [7]. In 1225 never-treated hypertensive patients plasma uric acid (PUA) levels were directly and independently associated with carotid-femoral PWV, but negatively associated with augmentation index (Alx), a variable of wave reflections [8]. In the Baltimore Longitudinal Study of Aging, higher serum uric acid was associated with greater increase in PWV in men but not in women during 6 years of follow-up [9]. However, this association was lost when men with PUA ≥ 370 µmol/l were excluded, suggesting a threshold for uric acid association with arterial stiffness [9]. A report from the Framingham heart study suggested that every 60 µmol/l increase in uric acid resulted in a 0.04 m/s ($p = 0.016$) increase in carotid-to-femoral PWV when hypertensive subjects were excluded [10]. A recent cross-sectional study found that PWV was higher in medicated hypertensive subjects with hyperuricemia than in hypertensive subjects without hyperuricemia [11]. Also a meta-analysis containing information from 24 publications supported the view that serum uric acid is related to higher carotid-femoral PWV in the general population [4]. However, the matter remains controversial, as serum uric acid was not, but uric acid-to-creatinine ratio in the urine was related to the risk of having higher PWV in 2296 Chinese subjects with a mean age of 43 years [12].

Previously the plasma concentration of uric acid has been related with the level of blood pressure [13], arterial stiffness [4, 9, 11, 14], wave reflections [8, 15], and markers of endothelial injury [16]. In this cross-sectional study our objective was to examine the association of uric acid with several functional hemodynamic variables in a generally healthy population with uric acid concentrations predominantly within the normal range. The present results suggest an independent relation between uric acid and large arterial stiffness, but no association between uric acid and blood pressure (BP), cardiac output, systemic vascular resistance, or wave reflection.

Methods
Study subjects
The recruitment of the study subjects has been previously described [17–19]. All subjects were examined by a physician, office BP was measured, and laboratory analyses were taken as previously described [20]. Laboratory samples were taken 12 (10, 13) days, and medical examination performed 8 (4, 13) days [mean (95% confidence internal, CI)] before the hemodynamic measurements. Medical history, lifestyle behavior and family history were documented. Alcohol use was evaluated as consumption of standard drinks (~ 12 g of absolute alcohol) per week and categorized to low, moderate, high according to the prevailing Finnish guidelines [21]. Smoking amount was estimated in pack-years. All subjects with BP lowering or uric acid level altering medications were excluded. The other exclusion criteria were history of coronary artery disease, stroke, cardiac insufficiency, valvular heart disease, chronic kidney disease, secondary hypertension, alcohol or substance abuse, psychiatric illness other than mild to moderate depression or anxiety, heart rhythm other than sinus rhythm, and ongoing pregnancy. Altogether 606 subjects, aged 20–72 years, participated in the study. The study was registered in two international databases of clinical studies (Eudra-CT registration number 2006-002065-39, ClinicalTrials.gov NCT01742702).

The following stable medications were used by the participants: female hormones for contraception or hormone replacement therapy (n = 63), antidepressants (40), vitamin D supplements (39), hormone-releasing intrauterine devices (24), thyroxin (21), inhaled glucocorticoids (17), antihistamines (16), statins (14), proton pump inhibitors (13), calcium supplementation (10), antirheumatics (6), low dose acetylsalicylic acid (6), anxiolytics (6), inhaled β2-mimetics (4), non-steroidal anti-inflammatory drugs (3), coxibs (3), pregabaline or gabapentin (3), antiepileptics (2), varenicline (2), warfarin (2), isotretinoin (1), ezetimibe (1), and tramadol (1).

Laboratory analyses
Blood and urine samples were taken after about 12 h of fasting. Plasma C-reactive protein (CRP), sodium, potassium, glucose, creatinine, uric acid, triglyceride, and total, high-density (HDL) and low-density lipoprotein (LDL) cholesterol concentrations were determined using Cobas Integra 800 (F. Hoffmann-LaRoche Ltd, Basel, Switzerland). Insulin and parathyroid hormone (PTH) were determined using electrochemiluminescence immunoassay (Cobas e411, Roche Diagnostics). Estimated glomerular filtration rate (eGFR) was calculated using the
aged 18–49 years, and 155–400 µmol/l for women aged ≥ 50 years [24].

Experimental protocol
Hemodynamic recordings were performed in a noiseless, temperature-controlled laboratory [17, 18, 25]. Products containing caffeine, smoking or heavy meal were to be avoided for ≥ 4 h, and alcohol consumption for ≥ 24 h before the investigation. The subjects rested supine on the examination table with impedance cardiography electrodes placed on body surface, tonometric sensor for pulse wave analysis on left radial pulsation, and oscillometric brachial cuff for BP calibration to the right upper arm. The left arm with the tonometric sensor was abducted to 90° in a support, which held the measurement probe at the heart level.

The measurement consisted of one 5-min period with continuous capture of hemodynamic data. For the analyses, the mean values of each 1-min period of recording were calculated. The repeatability and reproducibility of the protocol has been demonstrated to be good [17, 18, 25].

Pulse wave analysis
Radial BP and pulse wave were continuously recorded by a tonometric sensor (Colin BP-508 T, Colin Medical Instruments Corp., USA) [17, 18]. The radial BP was calibrated approximately every 2.5 min by brachial BP measurements. Aortic BP was derived with the validated SphygmoCor pulse wave monitoring system (SpygmoCor PWVMx, AtCor medical, Australia) [26]. Aortic pulse pressure and augmentation index (augmented pressure/pulse pressure * 100) were also determined. Central forward wave amplitude was defined as the difference between waveform foot and first systolic inflection point pressure in the aortic waveform [27, 28].

Whole-body impedance cardiography
We used whole-body impedance cardiography (CircMon®, JR Medical Ltd., Tallinn, Estonia) that records changes in body electrical impedance during cardiac phases to measure heart rate, stroke volume, cardiac output, and PWV [29, 30]. Systemic vascular resistance was calculated from radial BP and cardiac output measured by CircMon®. Stroke volume, cardiac output and systemic vascular resistance were presented as indexes related to body surface area calculated using the DuBois equation [31]. The method and electrode configuration have been previously reported [30, 32]. Briefly, current electrodes were placed on the distal parts of the extremities proximally to the wrists and the ankles. Voltage electrodes were placed about 5 cm proximally to the current electrodes. To record the distal impedance from the popliteal artery at knee joint level, an active electrode was placed on the lateral side of the knee and the reference electrode on the calf about 20 cm apart. When the pressure wave enters the aortic arch and the diameter of the aorta changes, the voltage electrodes on the distal parts of the extremities record the decrease in whole-body impedance. PWV is calculated from the time difference between the onset of the decrease (‘foot’) in the whole-body impedance and the popliteal artery signal, and the distance between the electrodes [30, 32].

With CircMon® the recorded stroke volume and cardiac output are in good agreement with values obtained utilizing 3 dimensional echocardiography [25] and the thermodilution and direct oxygen Fick methods [29, 32], and the PWV values show very good correlation with values measured using ultrasound or the tonometric method [30, 33].

Statistics
The normally distributed data was analyzed using analysis of variance, non-normally distributed data using Kruskal-Wallis test with Mann–Whitney U-test in the post-hoc analyses. The Bonferroni correction was applied in all post-hoc analyses. IBM SPSS Statistics Version 26 (IBM Corporation, Armonk, NV, USA) was used for statistics. The results in the tables were presented as means and standard errors of the mean (SEM), or median [25th–75th percentiles], and in the figures as means and 95% confidence intervals of the mean. p < 0.05 was considered significant. The hemodynamic values were calculated as averages from the minutes 3–5 of the recordings when the signal was most stable. For the analyses, the subjects were divided into quartiles of PUA concentration that were adjusted for sex; or age, sex, and body mass index (BMI), as appropriate. Proportions on subjects in the PUA quartiles were compared using the Chi-square test. The use of the medications listed above did not differ between the quartiles of PUA.

For the statistical analyses, the continuous variables not normally distributed were Lg10-transformed. Linear regression analyses with stepwise elimination were used to investigate factors independently associated with hemodynamic variables. The covariates in the...
analyses were age, sex, BMI, alcohol consumption category (low, moderate, high) [21], smoking status (never, current, previous); plasma calcium, phosphate, PTH, log_{10} of triglycerides, HDL cholesterol, LDL cholesterol, uric acid, renin, aldosterone, log_{10} of CRP, sodium; log_{10} of QUICKI, eGFR, log_{10} of PWV, and mean aortic pressure, as appropriate.

Results
Study population and laboratory values
The PUA concentrations (mean ± SEM) were 344 ± 4 µmol/l in men and 258 ± 3 µmol/l in women (p < 0.001). The sex-adjusted demographic characteristics of the study participants according to PUA quartiles are shown in Table 1. Subject age was higher in quartile (Q) 4 versus Q1, while weight was higher in Q3 and Q4 than in Q1 and Q2. No difference was observed in height, whereas BMI was higher in Q3 than in Q2 and Q1 and highest of all in Q4.

Because of the above differences, the laboratory values in Table 2 are presented in sex, age and BMI adjusted quartiles of PUA, the concentrations of which were 234, 278, 314, and 373 µmol/l, respectively. Office systolic BP was higher in Q4 than in Q1, while office diastolic BP was higher in Q3 and Q4 than in Q1. The proportion of subjects with office hypertension (BP ≥ 140/90 mmHg) [20] was higher in Q3 than in Q1. No differences were observed in office heart rate, percentage of smokers, average alcohol intake, plasma electrolyte concentrations, or urine albumin excretion between the quartiles (Table 2). Plasma CRP was slightly higher in Q4 versus Q1 and Q2, while plasma renin activity, and plasma concentrations of aldosterone, PTH, and eGFR were corresponding in all quartiles. No differences were observed in fasting plasma total cholesterol, HDL cholesterol, glucose, and insulin, while QUICKI was lower in Q4 than in Q1. Plasma triglyceride concentration was higher in Q4 and Q3 when compared with Q1, and in Q4 versus Q2, whilst LDL cholesterol was somewhat higher in Q3 than in Q1.

Hemodynamic measurements
The results representing the hemodynamic variables in the age, sex and BMI adjusted quartiles of PUA are shown in Figs. 1, 2 and 3. No differences were observed in radial BP, calibrated from contralateral brachial BP measurements, or aortic BP between the quartiles (Fig. 1A–D).

Aortic pulse pressure, forward wave amplitude and augmentation index were similar in all quartiles (Fig. 2A–C), but aortic to popliteal PWV was higher in Q4 versus Q3 and Q1 (Fig. 2D). When analyzed separately in men and women, PWV was higher in Q4 versus Q1 in men (Fig. 2E), while in women no significant differences in PWV between the PUA quartiles were detected (Fig. 2F). The Pearson correlation between PUA concentration and PWV was 0.351 among all study subjects (p < 0.001), 0.338 in women (p < 0.001), and 0.242 in men (p < 0.001).

No differences were found between the quartiles in heart rate, stroke volume, cardiac output, and systemic vascular resistance (Fig. 3A–D).

Hemodynamic variables in linear regression analyses
The results of the linear regression analyses with stepwise elimination are presented in Tables 3 and 4. The independent explanatory factors for aortic systolic (R^2 = 0.399) and diastolic BP (R^2 = 0.350) were PWV, eGFR, plasma concentrations of calcium and PTH, and QUICKI (Table 3). In addition, LDL cholesterol and triglycerides were independently associated with systolic BP, while male sex and high alcohol consumption category showed independent associations with diastolic BP (Table 3).

The independent explanatory factors for PWV were age, ejection duration, mean aortic pressure, PUA, plasma triglycerides, BMI, and current smoking (R^2 = 0.591) (Table 1). If subjects with PUA ≥ 370 µmol/l were excluded from the regression analysis [9], PUA concentration was still associated with PWV in the remaining 507 participants (beta = 0.003, p = 0.006). Altogether the present analyses suggested that for every 100 µmol/l increase in PUA, the associated increase in PWV was 0.9 m/s.

The explanatory variables for PWV were then analyzed separately for sexes (Table 4). In women, the explanatory variables for PWV were age, mean aortic pressure, heart rate, plasma triglycerides, and PUA (R^2 = 0.580). In men, the explanatory variables for PWV were age, ejection duration, PUA, mean aortic pressure, BMI, and LDL cholesterol (R^2 = 0.532).

Table 1 Results of the study participants in sex adjusted quartiles of fasting plasma uric acid concentrations

|                | Q1 n=141 | Q2 n=155 | Q3 n=165 | Q4 n=144 |
|----------------|----------|----------|----------|----------|
| Male/female (n) | 74/77    | 73/79    | 76/77    | 72/78    |
| Age (years)     | 43.7 (0.96) | 44.3 (0.95) | 44.3 (0.95) | 47.5 (0.96)* |
| Weight (kg)     | 74.9 (1.2)  | 77.5 (1.2)  | 82.1 (1.2)*† | 86.5 (1.2)*† |
| Height (cm)     | 173.0 (0.8) | 172.9 (0.8) | 173.2 (0.8) | 172.8 (0.8) |
| Body mass index (kg/m²) | 24.9 (0.33) | 25.7 (0.33) | 27.3 (0.32)*† | 28.9 (0.33)*† |

Results shown as mean (standard error of mean)
*p < 0.05 versus Q1; †p < 0.05 versus Q2; **p < 0.05 versus Q3
In additional regression analyses, PUA was not an explanatory factor for forward wave amplitude, augmentation index, systemic vascular resistance, stroke volume, heart rate, or cardiac output (data not shown).

**Discussion**

In this study, we investigated the association of uric acid with several cardiovascular variables in normotensive subjects and in never-medicated hypertensive patients without cardiovascular disease or gout. In analyses adjusted for confounding factors, PUA was significantly associated with PWV but not with any other hemodynamic variables including radial and aortic BP. The linear regression analyses confirmed that PUA was an independent explanatory factor for PWV, an acknowledged marker of large arterial stiffness [7, 34]. Even when subjects with PUA ≥ 370 µmol/l were excluded [9], PUA concentration remained a significant independent variable related with PWV. Of note, PUA levels were predominantly within the normal range in the present population: only 8/295 men and 7/311 women presented with PUA exceeding the current national upper limits of normal values. Increased arterial stiffness is a strong predictor of cardiovascular events [34], and higher uric acid concentration may thus predispose to the future development of CVD. The average PWV values in the present study were within the normal range for subjects with high-normal BP or grade 1 hypertension [35, 36].

Previous studies have linked uric acid with arterial stiffness, but the matter remains controversial [14, 37]. In a cross-sectional study comprising 651 medicated hypertensive patients and normotensive controls, serum uric acid levels were positively correlated with PWV, even after adjusting for confounding factors. However, the association was stronger in patients with higher BP, suggesting a potential role for uric acid in the development of arterial stiffness and CVD. Further research is needed to clarify the complex relationship between uric acid and arterial stiffness in different populations.
Acid was independently associated with carotid-femoral PWV (CF-PWV) [11]. Hypertensive patients with hyperuricemia also presented with higher CF-PWV than hypertensive patients without hyperuricemia [11]. In a large hypertensive population from China comprising 10,450 participants, of whom >90% were receiving antihypertensive agents and ~50% were current smokers, serum uric acid was a risk factor for higher brachial-ankle PWV in men and women [38]. As a major difference to our study, medicated hypertensive subjects were included in the analyses of the above studies [11]. In the Framingham study, Mehta et al. found that uric acid was linked to CF-PWV in subjects with low cardiovascular risk factors, independent of BP [10]. However, when the medicated hypertensive patients were excluded from the analyses, the relation between uric acid and arterial stiffness was much weaker, albeit still statistically significant [10]. In 222 untreated hypertensive subjects without gout, PUA correlated with carotid-femoral PWV but not with 24-h systolic or diastolic BP in univariate analysis, however the association with PWV was no longer significant after correction for albuminuria and other covariates [39]. The above findings suggested that the association of uric acid with large arterial stiffness was not solely explained by the presence of hypertension. Fang et al. examined the relationship of serum uric acid with brachial-ankle PWV in apparently healthy 7025 subjects, and found a significant association in women but not in men [40]. Bian et al. found similar results in their cross-sectional analysis of 2374 subjects, in which elevated uric acid was associated with CF-PWV only in women [15]. On the other hand, in a healthy middle-aged population, serum uric acid was associated with CF-PWV in men but not in women. However, the results were not adjusted for eGFR, insulin resistance, or plasma lipids [41]. In contrast, Cicero et al. reported that uric acid was significantly associated with hypertension and carotid artery intima-media thickness, but not with CF-PWV in 619 subjects not taking antihypertensive, antidiabetic, lipid-lowering and uric-acid-lowering drugs [37].

A possible causal role for uric acid in the development of CVD is still unclear, and no consensus has been reached whether uric acid is a true risk factor or merely a marker of increased risk. However, several mechanisms have been suggested by which hyperuricemia could be linked to cardiovascular pathophysiology. Hyperuricemia may be associated with decreased nitric oxide production, and the resultant endothelial dysfunction could contribute to the development of increased arterial stiffness [16]. Experimental hyperuricemia has been characterized by decreased serum concentration of nitric oxide, while this was reversed by the lowering of uric acid levels using allopurinol [42]. Furthermore, xanthine oxidase inhibition with allopurinol was found to improve endothelium-dependent vasodilatation in the forearm of patients with heart failure and type 2 diabetes [43, 44]. However, the
Fig. 2  Aortic pulse pressure (A), forward wave amplitude (B), augmentation index (C), and pulse wave velocity (D) in 606 all subjects, and pulse wave velocity separately in men (E) and women (F), presented in age, body mass index, sex, C-reactive protein, triglyceride, and LDL cholesterol adjusted quartiles of plasma uric acid concentration; mean ± 95% confidence interval of the mean.
interpretation of the above findings is complicated by the potent antioxidant properties of uric acid both in vitro and in vivo [45, 46]. It is therefore possible that the culprit behind impaired endothelial function is the oxidative stress induced by xanthine oxidase activity and not uric acid per se. Indeed, George et al. reported that improved endothelial function induced by allopurinol was due to its ability to reduce vascular oxidative stress and not in its ability to reduce uric acid [47]. Of note, Feig et al. found that treatment of newly diagnosed hypertensive adolescents with allopurinol reduced their BP in the short term [13].

The tonometric recording of PWV is considered the gold standard method for the evaluation of large arterial stiffness [7, 34]. PWV measured by the tonometric recording of arterial pulsations was even found to predict future hypertension in elderly participants of the Framingham study [27]. Aortic-to-popliteal PWV, determined using the same impedance cardiography method that was applied in the present study, was also found to predict future hypertension in young adults [48]. Previously, we reported an excellent correlation (r = 0.82) between applation tonometric measurements of carotid-femoral PWV and impedance cardiography measurements of aortic-to-popliteal PWV in 80 subjects [33]. The impedance-derived PWV has also been validated against the measurement of PWV using ultrasound [30]. Based on the above findings, PWV recorded using whole-body impedance cardiography can be regarded as a reliable measure of large arterial stiffness [30, 33, 48].

We found that office BP was significantly higher in Q4 versus Q1 of PUA, even after adjusting for differences in age, sex, and body mass index (Table 2). However, the present measurements performed in supine position under quiet standardized laboratory conditions did not uncover any significant differences in peripheral or central BP between the PUA quartiles. Previously, white-coat hypertension was reported to be independently associated with higher large arterial stiffness in treated hypertensive patients [49]. Furthermore, when evaluated using the ratio of pulse pressure to stroke volume, higher arterial stiffness was also significantly related to the white-coat effect in 2778 hypertensive patients [50]. As the present quartile with the highest PUA (Q4) also presented with the highest PWV, increased large arterial stiffness may be the plausible explanation for the higher office BP in these subjects versus Q1, because of the link between the white-coat effect and large arterial stiffness [49, 50].

Our study has limitations that need to be acknowledged. PUA and hemodynamics were recorded at single points of time about 12 (10, 13) days apart (mean (95% CI)), and the cross-sectional design does not allow conclusions about causality. We cannot rule out a selection bias caused by the recruitment and exclusion protocol. We applied indirect non-invasive methods requiring mathematical processing to derive PWV, stroke volume
and cardiac output from the bioimpedance signal [32], and central aortic BP waveform from applanation tonometry signal [26]. Even though the methods have been validated against direct or invasive measurements [25, 29, 30], the results must be interpreted with caution. However, the approach to examine central hemodynamics, compared to just focusing on radial or brachial artery pressure, may be better related with the level of cardiovascular risk [51, 52]. Lastly, we cannot rule out potential multicollinearity problems that were not controlled for by the statistical methods, as some of the clinical characteristics and biochemical variables are strongly associated with each other.

### Conclusions

A direct association between PUA and PWV was observed in 606 normotensive and never-treated hypertensive subjects without cardiovascular disease or gout. The finding that PUA was not significantly associated with any other hemodynamic variable implies that PUA potentially plays a role in the pathogenesis of large arterial stiffness. Prospective longitudinal studies are needed to confirm the present finding.

### Abbreviations

BP: Bloodpressure; BMI: Bodymass index; CVD: Cardiovasculardisease; CF-PWV: Carotid-femoral pulse wave velocity; eGFR: Estimatedglomerular filtration rate; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; PTH: Parathyroid hormone; eGFR estimated glomerular filtration rate from plasma cystatin-C using the CKD-EPI formula [15].

### Acknowledgements

The authors are deeply grateful to research nurses Paula Erkkilä and Reeta Kumlah for invaluable technical assistance. The authors sincerely acknowledge CSC – IT Center for Science, Finland, for computational resources.

### Table 3

| Systolic blood pressure (mmHg) | B   | Beta  | p     | Diastolic blood pressure (mmHg) | B   | Beta  | p     |
|-------------------------------|-----|-------|-------|---------------------------------|-----|-------|-------|
| $R^2 = 0.399$                 |     |       |       | $R^2 = 0.350$                   |     |       |       |
| (constant)                    | -24.905 |       | <0.001 | (constant)                      | -23.172 |       | <0.001 |
| $\text{Lg}_{10}$ of pulse wave velocity | 81.312 | 0.384 | <0.001 | $\text{Lg}_{10}$ of pulse wave velocity | 47.287 | 0.333 | <0.001 |
| eGFR                          | -0.188 | -0.174 | <0.001 | Calcium                         | 20.013 | 0.159 | <0.001 |
| Calcium                       | 23.794 | 0.127 | <0.001 | PTH                             | 1.013 | 0.128 | 0.001 |
| PTH                           | 1.248 | 0.106 | 0.003 | eGFR                            | -0.115 | -0.159 | <0.001 |
| LDL                           | 3.173 | 0.150 | <0.001 | $\text{Lg}_{10}$ of QUICKI      | -34.464 | 0.384 | <0.001 |
| $\text{Lg}_{10}$ of QUICKI    | -40.982 | -0.102 | 0.007 | High alcohol consumption category | 7.565 | 0.083 | 0.020 |
| LDL of triglycerides          | -7.905 | -0.091 | 0.030 | Sex (male)                      | 2.103 | 0.080 | 0.029 |

Variables in Model: Age, sex, body mass index, alcohol consumption category (low, moderate, high), smoking status (current, previous), plasma uric acid, sodium, calcium, phosphate, PTH, HDL cholesterol, LDL cholesterol, eGFR, $\text{Lg}_{10}$ of triglycerides, C-reactive protein, renin, aldosterone, QUICKI, pulse wave velocity, LDL low-density lipoprotein, HDL high-density lipoprotein, QUICKI quantitative insulin sensitivity check index, PTH parathyroid hormone, eGFR estimated glomerular filtration rate from plasma cystatin-C using the CKD-EPI formula [15].

### Table 4

| Pulse wave velocity (m/s) | B   | Beta  | p     | Men and women, $R^2 = 0.591$ | B   | Beta  | p     | Women, $R^2 = 0.580$ | B   | Beta  | p     | Men, $R^2 = 0.532$ | B   | Beta  | p     |
|---------------------------|-----|-------|-------|-------------------------------|-----|-------|-------|-----------------------|-----|-------|-------|---------------------|-----|-------|-------|
| $R^2 = 0.591$             |     |       |       | (constant)                    | -0.025 |       | <0.001 | (constant)                      | 7.494 |       | <0.001 | (constant)                    | 9.747 |       | <0.001 |
| Age                       | 0.076 | 0.501 | <0.001 | Age                            | 0.076 | 0.501 | <0.001 | Age                                | 0.076 | 0.501 | <0.001 | Age                                | 0.084 | 0.501 | <0.001 |
| Ejection duration         | -0.020 | -0.223 | <0.001 | Mean aortic pressure           | 0.022 | 0.180 | <0.001 | Heart rate                       | 0.032 | 0.187 | <0.001 | Mean aortic pressure           | 0.023 | 0.221 | <0.001 | Heart rate                       | 0.032 | 0.187 | <0.001 |
| Mean aortic pressure      | 0.004 | 0.168 | <0.001 | Heart rate                       | 0.032 | 0.187 | <0.001 | LDL cholesterol                | 0.004 | 0.168 | <0.001 | Uric acid                        | 0.006 | 0.171 | <0.001 | LDL cholesterol                | 0.006 | 0.171 | <0.001 |
| Body mass index           | 0.032 | 0.077 | 0.019 | LDL cholesterol                | 0.032 | 0.077 | 0.019 | Mean aortic pressure           | 0.006 | 0.171 | <0.001 | LDL cholesterol                | 0.006 | 0.171 | <0.001 | Uric acid                        | 0.006 | 0.171 | <0.001 |
| LDL of triglycerides      | 0.557 | 0.069 | 0.034 | Mean aortic pressure           | 0.006 | 0.171 | <0.001 | Mean aortic pressure           | 0.006 | 0.171 | <0.001 | Mean aortic pressure           | 0.025 | 0.164 | 0.001 | Mean aortic pressure           | 0.025 | 0.164 | 0.001 |
| Current smoking           | -0.363 | -0.067 | 0.015 | Current smoking                | 0.003 | 0.090 | 0.032 | Current smoking                | 0.003 | 0.090 | 0.032 | Current smoking                | 0.003 | 0.090 | 0.032 | Current smoking                | 0.003 | 0.090 | 0.032 |

Variables in Model: Age, sex, body mass index, alcohol consumption category (low, moderate, high), smoking status (current, previous), mean aortic pressure, heart rate, ejection duration, eGFR, uric acid, HDL cholesterol, LDL cholesterol, $\text{Lg}_{10}$ of triglycerides, C-reactive protein, and QUICKI. LDL high-density lipoprotein, QUICKI quantitative insulin sensitivity check index, eGFR estimated glomerular filtration rate from plasma cystatin-C using the CKD-EPI formula [22].
Authors' contributions
HH, VK and IP reviewed the literature and performed the statistical analyses. HH, IP and JK wrote the original version of the manuscript. VK, IP and JK carried out the clinical examinations of patients. HH, MKC, HB, MAPK, JM, IP and JK participated in the design of the technical details and setting up of the methodology. ON was responsible for the laboratory analyses. All authors contributed to the interpretation of results, construction of the discussion and editing the manuscript. IP and JK were the responsible persons for designing and conducting the study. All authors take the responsibility for the contents of the manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by the Finnish Foundation of Cardiovascular Research, Paavo Nurmi Foundation, Sigrid Jusélius Foundation, Pirkanmaa Regional Fund of the Finnish Cultural Foundation, the Finnish Medical Foundation, and Competitive Research Funding of the Pirkanmaa Hospital District (grants 9V054 and 9X046).

Availability of data and materials
Analyses and generated datasets during the current study are not available publicly as our clinical database contains several indirect identifiers and the informed consent obtained does not allow publication of individual patient data. The datasets are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study protocol and all methods conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The study protocol and all methods were approved by the Ethics Committee of the Tampere University Hospital (study code R06086M) and the Finnish Medicines Agency (Eudra-CT registration number 2006-002065-39). Signed informed consent was obtained from all participants. All methods and equipment had also been inspected and approved for clinical use at Tampere University hospital.

Consent for publication
Not applicable.

Competing interests
The authors have no potential competing interests associated with this research.

Author details
1Faculty of Medicine and Health Technology, Tampere University, FI-33014 Tampere, Finland. 2Laboratory and Medical Research Unit, Seinäjoki Central Hospital, Seinäjoki, Finland. 3Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland. 4Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.

Received: 23 November 2020 Accepted: 19 May 2021
Published online: 26 May 2021

References
1. WHO-web-page. Cardiovascular diseases. 2017. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed 25 Feb 2020.
2. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;213:1–4.
3. Li X, Meng X, Timofeeva M, Tzoulaki I, Handysides JK, Ioannidis PA, et al. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ. 2017;357:j2376.
4. Rebeca P, Andreano A, Triglione N, Piccinelli E, Palazzini M, Occhioni L, et al. Association between uric acid and pulse wave velocity in hypertensive patients and in the general population: a systematic review and meta-analysis. Blood Press. 2020;29:212–31.
5. Laurent S, Matsah HD, Fassot C, Tropeano A-I, Gautier I, Laloux B, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke. 2003;34:1203–8.
6. Mattace-Raso FUS, van der Cammen TJM, Hofman A, van Popele NM, Bos ML, Schalekamp MAEH, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113:657–63.
7. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588–605.
8. Vlachopoulos C, Patlaganti P, Vyssoulis G, Briasas A, Baou K, Tzamou V, et al. Association of serum uric acid level with aortic stiffness and arterial wave reflections in newly diagnosed, never-treated hypertension. Am J Hypertens. 2011;24:33–9.
9. Canepa M, Viazzi F, Strait JB, Ameri P, Pontremoli R, Brunelli C, et al. Longitudinal association between serum uric acid and arterial stiffness. Hypertension. 2017;69:228–35.
10. Mehta T, Nuccio E, McFarrn K, Madero M, Sarnak MJ, Jalkal D. Association of uric acid with vascular stiffness in the Framingham heart study. Am J Hypertens. 2015;28:877–83.
11. Liu J, Wang K, Liu H, Zhao H, Zhao X, Lan Y, et al. Relationship between carotid-femoral pulse wave velocity and uric acid in subjects with hypertension and hyperuricaemia. Endocr J. 2019;66:629–36.
12. Wang Y, Zhang X-Y, Gao W-H, Du M-F, Chu C, Wang D, et al. Association of uric acid in serum and urine with arterial stiffness: Hanzhong adolescent hypertension dis. Dis Markers. 2020. https://doi.org/10.1155/2020/1638515.
13. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924.
14. Cassano V, Crescibene D, Hribal ML, Pelaia C, Armentano G, Magurno M, et al. Uric acid and vascular damage in essential hypertension: role of insulin resistance. Nutrients. 2020;12:2509.
15. Bian S, Guo H, Ye P, Luo L, Wu H, Xiao W. Serum uric acid level and diverse impacts on regional arterial stiffness and wave reflection. Iran J Public Health. 2012;41:33–41.
16. Zhen H, Gui F. The role of hyperuricemia on vascular endothelial dysfunction. Biomed Rep. 2017;7:325–30.
17. Tahvanainen A, Koskela J, Tikkakoski A, Lahtela J, Leskinen M, Kähönen M, et al. Analysis of cardiovascular responses to passive head-up tilt using continuous pulse wave analysis and impedance cardiography. Scand J Clin Lab Invest. 2009;69:128–37.
18. Tikkakoski AJ, Tahvanainen AM, Leskinen MH, Koskela JK, Haring A, Viitala J, et al. Hemodynamic alterations in hypertensive patients at rest and during passive head-up tilt. J Hypertens. 2013;31:906–15.
19. Kangas P, Tikkakoski A, Tahvanainen A, Koskela J, Kähönen M, Kööbi T, et al. Changes in hemodynamics associated with metabolic syndrome are more pronounced in men than in women. Sci Rep. 2019;9:18377.
20. Williams B, Mancua G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. J Hypertens. 2018;36:1953–2041.
21. Finnish guidelines for the current care of subjects with alcohol problem. 2015. http://www.kaypahoito.fi/web/kh/suositukset/suositus?id=hoi05028#NaN. Accessed 15 Nov 2020.
22. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9. doi:https://doi.org/10.1056/NEJMoa1114248.
23. Katz A, Nambi SS, Mather K, Baron AD, Pollmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.
24. Fimlab-Laboratories-Ltd. Normal values and interpretation of results for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.
25. Koskela JK, Tahvanainen A, Haring A, Tikkakoski AJ, Ilveskoski E, Viitala J, et al. Association of resting heart rate with cardiovascular function: a cross-sectional study in 522 Finnish subjects. BMC Cardiovasc Disord. 2013;13:102.
radial tonometry pressure. Validation of generalized transfer function. Circulation. 1997;95:1827–36.
27. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA. 2012;308:875–81.
28. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004;43(4):1239–45.
29. Kööbi T, Kaukinen S, Ahola T, Turjanmaa V. Non-invasive measurement of cardiac output: whole-body impedance cardiography in simultaneous comparison with thermodilution and direct oxygen Fick methods. Intensive Care Med. 1997;23(11):132–7.
30. Kööbi T, Kahonen M, Ivainen T, Turjanmaa V. Simultaneous non-invasive assessment of arterial stiffness and haemodynamics—a validation study. Clin Physiol Funct Imaging. 2003;23:31–6.
31. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–71.
32. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–71.
33. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–27.
34. Koivistoinen T, Lyytikäinen L-P, Aatola H, Luukkaala T, Juonala M, Viikari J, et al. Pulse wave velocity predicts the progression of blood pressure and development of hypertension in young adults. Hypertension. 2018;71:451–6.
35. Barochiner J, Aparicio LS, Alfie J, Morales MS, Cuffaro PE, Rada MA, et al. Arterial stiffness in treated hypertensive patients with white-coat hypertension. J Clin Hypertens. 2017;19:196–10.
36. de Simone G, Schillaci G, Chinali M, Angeli F, Reboldi GP, Verdecchia P. Estimate of white-coat effect and arterial stiffness. J Hypertens. 2007;25:779–85.
37. Wilenius M, Tikkakoski AI, Tahvanainen AM, Haring A, Koskela J, Huhtala H, et al. Central wave reflection is associated with peripheral arterial resistance in addition to arterial stiffness in subjects without antihypertensive medication. BMC Cardiovasc Disord. 2016;16:131.
38. Vlachopoulos C, Azmaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–27.
39. Koivistoinen T, Kööbi T, Jula A, Hutti-Kahonen N, Raitakari OT, Majahalme V, et al. Central wave reflection is associated with peripheral arterial resistance in addition to arterial stiffness in subjects without antihypertensive medication. BMC Cardiovasc Disord. 2016;16:131.
40. Cicero AFG, Salvi P, D’Addato S, Rostico C, Borghi C. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens. 2014;32:57–64.
41. Koivistoinen T, Kaukinen S, Ahola T, Turjanmaa V. Simultaneous non-invasive assessment of arterial stiffness and haemodynamics—a validation study. Clin Physiol Funct Imaging. 2003;23:31–6.
42. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004;43:1239–45.
43. Koivistoinen T, Kahonen M, Ivainen T, Turjanmaa V. Simultaneous non-invasive assessment of arterial stiffness and haemodynamics—a validation study. Clin Physiol Funct Imaging. 2003;23:31–6.
44. Vlachopoulos C, Azmaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–27.
45. Butler R, Morris AD, Belch JF, Hill A, Struthers Allan D. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35:746–51.
46. Kohsia UM, Zhankov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739–42.
47. Farquharson Colin A.J., Butler Robert, Hill Alexander, Belch Jill J.F., Struthers Allan D. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221–6.
48. Butler R, Morris AD, Belch JF, Hill A, Struthers Allan D. Allopurinol normalizes endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221–6.
49. George J, Carr E, Davies J, Belch JF, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508–16.
50. Koivistoinen T, Lyytikäinen L-P, Aatola H, Luukkaala T, Juonala M, Viikari J, et al. Pulse wave velocity predicts the progression of blood pressure and development of hypertension in young adults. Hypertension. 2018;71:451–6.
51. Roman MJ, Devereux RB, Kizer JR, T. LE, Galloway JM, Ali T, et al. Central wave reflection more strongly relates to vascular disease and outcome than brachial blood pressure. Circulation. 2005;111:197–203.
52. Kollias A, Lagou S, Zeniodi M, Elena B, Nadia S, George S. Association of serum uric acid level associated with increased arterial stiffness in hypertension. Atherosclerosis. 2014;236:389–93.
53. Koivistoinen T, Lyytikäinen L-P, Aatola H, Luukkaala T, Juonala M, Viikari J, et al. Central wave reflection is associated with peripheral arterial resistance in addition to arterial stiffness in subjects without antihypertensive medication. BMC Cardiovasc Disord. 2016;16:131.
54. Vlachopoulos C, Azmaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–27.
55. Koivistoinen T, Kööbi T, Jula A, Hutti-Kahonen N, Raitakari OT, Majahalme V, et al. Central wave reflection is associated with peripheral arterial resistance in addition to arterial stiffness in subjects without antihypertensive medication. BMC Cardiovasc Disord. 2016;16:131.
56. Koivistoinen T, Kööbi T, Jula A, Hutti-Kahonen N, Raitakari OT, Majahalme V, et al. Central wave reflection is associated with peripheral arterial resistance in addition to arterial stiffness in subjects without antihypertensive medication. BMC Cardiovasc Disord. 2016;16:131.
57. Koivistoinen T, Kööbi T, Jula A, Hutti-Kahonen N, Raitakari OT, Majahalme V, et al. Central wave reflection is associated with peripheral arterial resistance in addition to arterial stiffness in subjects without antihypertensive medication. BMC Cardiovasc Disord. 2016;16:131.
58. Koivistoinen T, Kööbi T, Jula A, Hutti-Kahonen N, Raitakari OT, Majahalme V, et al. Central wave reflection is associated with peripheral arterial resistance in addition to arterial stiffness in subjects without antihypertensive medication. BMC Cardiovasc Disord. 2016;16:131.
59. Koivistoinen T, Kööbi T, Jula A, Hutti-Kahonen N, Raitakari OT, Majahalme V, et al. Central wave reflection is associated with peripheral arterial resistance in addition to arterial stiffness in subjects without antihypertensive medication. BMC Cardiovasc Disord. 2016;16:131.
60. Koivistoinen T, Kööbi T, Jula A, Hutti-Kahonen N, Raitakari OT, Majahalme V, et al. Central wave reflection is associated with peripheral arterial resistance in addition to arterial stiffness in subjects without antihypertensive medication. BMC Cardiovasc Disord. 2016;16:131.
61. Koivistoinen T, Kööbi T, Jula A, Hutti-Kahonen N, Raitakari OT, Majahalme V, et al. Central wave reflection is associated with peripheral arterial resistance in addition to arterial stiffness in subjects without antihypertensive medication. BMC Cardiovasc Disord. 2016;16:131.